Patient and transplantation characteristics according to initial presentation
| Characteristic . | Acute onset (n = 352) . | Chronic onset (n = 388) . |
|---|---|---|
| Patient median age, y (range) | 37.2 (0.8-67.0) | 41.8 (1.4-66.4) |
| Disease at transplantation, no. (%) | ||
| Myelodysplastic syndrome | 48 (14) | 67 (17) |
| Acute myeloid leukemia | 71 (20) | 72 (19) |
| Chronic myeloid leukemia | 146 (41) | 151 (39) |
| Acute lymphoid leukemia | 52 (15) | 42 (11) |
| Chronic lymphoid leukemia | 4 (1) | 6 (2) |
| Non-Hodgkin lymphoma or Hodgkin disease | 10 (3) | 34 (9) |
| Multiple myeloma | 4 (1) | 7 (2) |
| Other* | 17 (5) | 9 (2) |
| Pretransplantation risk category, no. (%)† | ||
| Low | 142 (40) | 143 (37) |
| Intermediate | 150 (43) | 171 (44) |
| High | 60 (17) | 74 (19) |
| Donor median age, y (range) | 40.0 (0.0-81.7) | 39.0 (0.0-70.9) |
| Donor/recipient sex, no. (%) | ||
| Male/male | 122 (35) | 122 (31) |
| Male/female | 73 (21) | 87 (22) |
| Female/male | 90 (26) | 107 (28) |
| Female/female | 67 (19) | 72 (19) |
| Donor type, no. (%) | ||
| HLA-identical related | 152 (43) | 176 (45) |
| HLA-mismatched related | 35 (10) | 24 (6) |
| HLA-matched unrelated | 83 (24) | 101 (26) |
| HLA-mismatched unrelated | 82 (23) | 87 (22) |
| No. of mismatched HLA loci‡ (%) | ||
| 0 | 243 (69) | 282 (73) |
| 1 | 64 (18) | 65 (17) |
| 2 | 42 (12) | 29 (7) |
| More than 2 | 3 (1) | 12 (3) |
| Conditioning regimen, no. (%) | ||
| Cyclophosphamide and TBI | 196 (56) | 215 (55) |
| Busulfan and cyclophosphamide | 114 (32) | 127 (33) |
| Busulfan and TBI | 16 (5) | 26 (7) |
| Other | 26 (7) | 20 (5) |
| Source of stem cells, no. (%) | ||
| Bone marrow | 289 (82) | 302 (78) |
| Mobilized blood | 59 (17) | 85 (22) |
| Cord blood | 4 (1) | 1 (< 1) |
| GVHD prophylaxis, no. (%) | ||
| Cyclosporine plus methotrexate | 297 (84) | 329 (85) |
| Tacrolimus plus methotrexate | 12 (3) | 11 (3) |
| Other | 43 (12) | 48 (12) |
| Year of transplantation, no. (%) | ||
| 1994-1997 | 203 (58) | 217 (56) |
| 1998-2000 | 149 (42) | 171 (44) |
| Prior acute GVHD before day 100, no. (%) | ||
| Grade 0-I | 34 (10) | 69 (18) |
| Grade II | 222 (63) | 229 (59) |
| Grades III-IV | 96 (27) | 90 (23) |
| Characteristic . | Acute onset (n = 352) . | Chronic onset (n = 388) . |
|---|---|---|
| Patient median age, y (range) | 37.2 (0.8-67.0) | 41.8 (1.4-66.4) |
| Disease at transplantation, no. (%) | ||
| Myelodysplastic syndrome | 48 (14) | 67 (17) |
| Acute myeloid leukemia | 71 (20) | 72 (19) |
| Chronic myeloid leukemia | 146 (41) | 151 (39) |
| Acute lymphoid leukemia | 52 (15) | 42 (11) |
| Chronic lymphoid leukemia | 4 (1) | 6 (2) |
| Non-Hodgkin lymphoma or Hodgkin disease | 10 (3) | 34 (9) |
| Multiple myeloma | 4 (1) | 7 (2) |
| Other* | 17 (5) | 9 (2) |
| Pretransplantation risk category, no. (%)† | ||
| Low | 142 (40) | 143 (37) |
| Intermediate | 150 (43) | 171 (44) |
| High | 60 (17) | 74 (19) |
| Donor median age, y (range) | 40.0 (0.0-81.7) | 39.0 (0.0-70.9) |
| Donor/recipient sex, no. (%) | ||
| Male/male | 122 (35) | 122 (31) |
| Male/female | 73 (21) | 87 (22) |
| Female/male | 90 (26) | 107 (28) |
| Female/female | 67 (19) | 72 (19) |
| Donor type, no. (%) | ||
| HLA-identical related | 152 (43) | 176 (45) |
| HLA-mismatched related | 35 (10) | 24 (6) |
| HLA-matched unrelated | 83 (24) | 101 (26) |
| HLA-mismatched unrelated | 82 (23) | 87 (22) |
| No. of mismatched HLA loci‡ (%) | ||
| 0 | 243 (69) | 282 (73) |
| 1 | 64 (18) | 65 (17) |
| 2 | 42 (12) | 29 (7) |
| More than 2 | 3 (1) | 12 (3) |
| Conditioning regimen, no. (%) | ||
| Cyclophosphamide and TBI | 196 (56) | 215 (55) |
| Busulfan and cyclophosphamide | 114 (32) | 127 (33) |
| Busulfan and TBI | 16 (5) | 26 (7) |
| Other | 26 (7) | 20 (5) |
| Source of stem cells, no. (%) | ||
| Bone marrow | 289 (82) | 302 (78) |
| Mobilized blood | 59 (17) | 85 (22) |
| Cord blood | 4 (1) | 1 (< 1) |
| GVHD prophylaxis, no. (%) | ||
| Cyclosporine plus methotrexate | 297 (84) | 329 (85) |
| Tacrolimus plus methotrexate | 12 (3) | 11 (3) |
| Other | 43 (12) | 48 (12) |
| Year of transplantation, no. (%) | ||
| 1994-1997 | 203 (58) | 217 (56) |
| 1998-2000 | 149 (42) | 171 (44) |
| Prior acute GVHD before day 100, no. (%) | ||
| Grade 0-I | 34 (10) | 69 (18) |
| Grade II | 222 (63) | 229 (59) |
| Grades III-IV | 96 (27) | 90 (23) |
Twenty-four patients had diseases other than hematologic malignancies.
The low-risk category included chronic myeloid leukemia in chronic phase and aplastic anemia. The high-risk category included chronic myeloid leukemia in blast crisis, acute leukemia or lymphoma in relapse, refractory anemia with excess blasts in transformation, and myeloma. The intermediate-risk category included all other diseases.
HLA-C and -DQ typing was not available for 3 cord blood donors. HLA-C and -DQ typing was not available for one marrow donor at each locus.